Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup

Atlas Venture-backed Kyn Therapeutics hopes to create drugs that reverse the effects of a metabolite called kynurenine, which cancer cells use to suppress the immune system and ward off attacks.

Source: bizjournals.com Health Care:Physician Practices headlines - January 18, 2019 Category: American Health Authors: Allison DeAngelis Source Type: news